Among these, trametinib (also known as GSK1120212) stands out as a promising MEK1/2 inhibitor for HNSCC, effectively inhibiting MEK1 and MEK2 kinases, preventing RAF-dependent MEK phosphorylation, and resulting in prolonged pERK1/2 inhibition [12]. Here, MAP2K1 is linked to head and neck squamous cell carcinoma.